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1. Introduction
In this chapter the state of art of the pre-clinical evidences of cannabidiol (CBD) anti-tumour
effects on different kinds of cancer will be discussed. As you will see in the following para‐
graphs, CBD is a phytocannabinoid devoid of any psychotropic activity which exerts some of
its effects through modulation of different components of the endocannabinoid system. For a
more clear comprehension, a brief introduction on the endocannabinoid system itself is here
provided.
2. The endocannabinoid system: A brief overview
The endocannabinoid system (eCB) is a signalling system that consist of the cannabinoid
CB1 and CB2 receptors, their intrinsic lipid ligands, named endocannabinoids (eCBs), such as
the N-arachidonoylethanolamide (anandamide, AEA) and the 2-arachidonoylglycerol (2AG),
and the associated enzymatic machinery, comprising transporters, biosynthetic and degrada‐
tive enzymes. It has been recently discovered and was thoroughly explored by scientists in the
past 15 years.
The cannabinoid CB1 and CB2 receptors are G protein coupled receptors. CB1 receptors are
mainly present in the central nervous system (CNS) with low to moderate expression in
periphery; on the contrary, CB2 receptors are highly localized in the immune system with much
lower and more restricted distribution in the CNS [1,2].
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Soon after the characterization of the cannabinoid receptors came the discovery of their
endogenous ligands. The two major known endogenous ligands are anandamide (AEA) and
2-arachidonoylglycerol (2AG) [3-6]. Both derive from arachidonic acid and are produced
postsynaptically from phospholipid precursors through activity-dependent activation of
specific phospholipase enzymes [7]. Later on, a number of other eCB ligands have been
discovered including N-arachidonoyldopamine (NADA), N-arachidonoylglycerolether and
O-arachidonoylethanolamine [8].
AEA and 2AG are characterized by different biosynthetic and metabolic pathways, showing
distinct mechanisms of regulation. AEA can be synthesized through different pathways from
the phospholipid precursors N-arachidonoyl-phosphatidylethanolamine, the most important
of which is a direct conversion catalysed by an N-acyl-phosphatidylethanolamine selective
phosphodiesterase. 2AG principal way of synthesis is through activation of phospholipase C
and subsequent production of diacylglycerol, which is rapidly converted to 2AG by diacyl‐
glycerol lipase. After its re-uptake, AEA is hydrolysed by the enzyme fatty acid amide
hydrolase (FAAH), producing arachidonic acid and ethanolamine, while 2AG is primarily
metabolized by monoacylglycerol lipase (MAG lipase), leading to the formation of arachidonic
acid and glycerol [9]. eCBs may bind not only to the well known CB1 and CB2 receptors, but
also to other receptors. For instance, AEA may activate the potential vanilloid receptor type 1
(TRPV1) intracellularly [10]. Moreover, ‘orphan’ G protein coupled receptor, GPR55, has been
recently proposed as putative cannabinoid receptor [11], as has been the peroxisome prolifer‐
ator activated receptor, PPAR [12,13]. CB1 and CB2 receptors still remain the best known targets
for AEA and 2AG, though interacting with different affinity: AEA has the highest affinity to
both receptors, whereas 2AG has the highest efficacy on both receptors [14].
eCB synthesis can be induced by physiological or pathological stimuli and results in their
immediate release, with subsequent activation of cannabinoid receptors. Therefore eCBs are
synthesized and released “on demand” by post-synaptic cells, involving the cleavage of
membrane phospholipid precursors. Each member of the endocannabinoid machinery tightly
controls the synthesis, release and degradation of the eCBs, finely tuning the signalling system.
The eCB system has been found altered in several diseases, as multiple sclerosis and spinal
cord injury, neuropathic pain, cancer, atherosclerosis, stroke, myocardial infarction, hyper‐
tension, glaucoma, obesity/metabolic syndrome and osteoporosis, thus paving the way for
new therapeutic strategies aimed at restoring normal eCB system functionality [15].
Currently, the term ‘cannabinoid’ refers more than 100 terpenophenols derived from Cannabis
sativa [16], as well as to synthetic compounds that directly or indirectly interact with cannabi‐
noid receptors. The most psychoactive component of the plant Cannabis sativa is Δ9-tetrahy‐
drocannabinol (Δ9-THC): its biological actions as well as the ones of synthetic cannabinoid
compounds (synthetic compounds active on cannabinoid receptors) are primarily mediated
by CB1 and CB2 receptors. Cannabinoids classification comprises phytocannabinoids (subclas‐
sified in different categories according to their chemical structures, such as Δ9-THC, Δ8-THC,
cannabinol, CBD and cannabicyclol), synthetic compounds active on cannabinoid receptors
(i.e., JWH133, WIN55212-2, SR141716) and endocannabinoids (i.e., AEA and 2AG) which are
produced endogenously (Figure 1).
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Figure 1. Chemical structures of Δ9-tetrahydrocannabinol (Δ9-THC), cannabidiol (CBD), anandamide (AEA) and
WIN55212-2
3. Cannabinoids and cancer
Till now, most of cannabinoids applications in clinical practice of cancer patients comprised
palliate wasting, emesis and pain that often accompany cancer. The discovery of a potential
utility of these compounds for targeting and killing cancer cells led to a significant advance‐
ment in cannabinoid use in cancer treatment. In 1975 Munson et al. [17] demonstrated that the
administration of Δ9-THC, Δ8-THC and cannabinol inhibited the growth of Lewis lung
adenocarcinoma cells in vitro as well as in vivo after oral administration in mice. From then on,
the interest in anti-carcinogenic properties of cannabinoids substantially decreased, until the
discovery of the eCB system and the cloning of the specific cannabinoid receptors, CB1 and
CB2. In the past decades, more and more evidences have contributed to assess and define the
anti-tumourigenic effect of several cannabinoid compounds, including Δ9-THC, cannabidiol
(CBD), synthetic agonists, endocannabinoids and endocannabinoid transport or degradation
inhibitors. These molecules have proved valuable against tumour cell proliferation and
angiogenesis, and induce apoptosis in various cancer types, i.e. lung, glioma, thyroid, lym‐
phoma, skin, pancreas, uterus, breast, prostate and colorectal carcinoma, both in vitro and in
vivo [18-26]. Moreover, other mechanisms adopted by cannabinoids to counteract tumouri‐
genesis are currently emerging and comprise interference with tumour neovascularization,
cancer cell migration, adhesion, invasion and metastasisation [27].
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Notwithstanding these promising anti-tumour effects, the clinical application of Δ9-THC and
other cannabinoid agonists is often limited by their unwanted psychoactive side effects. In line
with this fact, in recent years increasing interest has been focused on non-psychoactive
cannabinoid compounds with structural affinity for Δ9-THC, such as cannabidiol (CBD).
Interestingly, although its very low affinity for both CB1 and CB2 receptors, CBD has been
recently reported to act with unexpectedly high potency in vitro as antagonist of CB1 receptors
in the mouse vas deferens [28] and brain [29] tissues, and to behave as inverse agonist at human
CB2 receptors [29]. Moreover, other putative CBD’s molecular targets are TRPV, 5-HT1A, GPR55
and PPARγ receptors (Figure 2).
Figure 2. Some of the potential biological targets of CBD (with the permission of the authors [30])
Several studies reported the beneficial effects of CBD in the treatment of pain and spasticity
and other CNS pathologies, as multiple sclerosis, Huntington disease, Parkinson etc. More‐
over, many reports demonstrated its anti-tumour effects: it is characterized by a pro-apoptotic
anti-metastatic activity and inhibits cancer cell migration, adhesion and invasion.
The aim of this chapter is to report the state of art on the efficacy of CBD in the modulation of
the different steps of tumourigenesis in several types of cancer. The results here presented
highlight the importance of future further exploration of CBD and/or of CBD analogues as
alternative agents for tumour therapy, at least for breast cancer, glioma, lung tumour and
leukaemia. The data available so far are summarized in Table 1 and are discussed in detail in
the following paragraphs.
4. CBD and breast cancer
In 2006 Ligresti et al. [31] first demonstrated that CBD potently and selectively inhibits the
proliferation of human breast cancer cells. This compound was able to strongly inhibit the
growth of different breast tumour cell lines (MCF7, MDA-MB-231) in vitro, with an IC50 of
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Breast
↓  proliferation CB2;TRPV1 ↑ NC NC +
↓  xenografts
growth
↓  lung
metastases
[26]
↓  viability
non-CB1;
non-CB2;
non-TRPV1
↑
↓  pAkt; ↑
cytochrome C
Bid translocation
+ + NC [29]
↓  invasion NC ↑ ↓  Id-1; ↑  pERK NC NC
↓  tumour growth
↓  size and
number of
metastases
[27,28]
Glioma
↓  proliferation
non-CB1;
partial-CB2;
non-TRPV1
↑
↓  pERK; ↓  pAkt; ↓
HIF-1α
↑  cytochrome C
caspase activation
NC + ↓  tumour growth[33,34,37,38]
↓  proliferation
and
invasiveness
NC NC NC NC NC NC [35]
↓  migration
non-CB1;
non-CB2;
non-TRPV1
NC Ptx insensitive NC NC NC [39]
↓  invasiveness NC NC ↓  Id-1 NC NC NC [46]
Leukaemia
↓  viability NC NC caspase-3 activation NC + NC [40]
↓  viability CB2 ↑
↓  p-p38
caspase activation; ↓
Bid
↑  cytochrome C
NC +
↓  tumour burden
↑  tumour cell
apoptosis
[41]
Lung ↓  invasion
CB1;
CB2;
TRPV1
NC
↑  p-p38; ↑  p-ERK; ↑
TIMP-1
↓  PAI-1
NC NC
↓  lung
metastases
↓  PAI-1 in
xenografts
[49,50]
Thyroid
Thymoma
cytostatic effect NC NC NC NC + NC [26]
↓  viability NC ↑ NC NC + NC [53]
Colon ↓  proliferation
CB1;
TRPV1;
PPARγ
NC ↓  Akt; ↑  2AG↑  caspase-3; ↑  COX-2 NC +
↓  ACF, polyps
and tumours [55]
NC=not checked ↑  increase; ↓ decrease
Table 1. Effects of CBD on different types of cancer
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about 6 μM. Worth to note, its effect on non cancer cells resulted far less potent. Further on,
by the use of xenografts obtained by s.c. injection into athymic mice of human MDA-MB-231
breast carcinoma, the authors demonstrated that CBD and CBD-rich extracts (containing
approximately 70% CBD together with lesser amounts of other cannabinoids) not only
inhibited tumour growth in vivo, but also reduced lung metastases deriving from intrapaw
injection of MDA-MB-231 cells. The possible cellular and molecular mechanisms underlying
these effects may include induction of a combination of mechanisms by CBD, involving direct
TRPV1 activation and/or CB2 indirect activation (via FAAH), as well as induction of oxidative
stress.
Subsequent work form McAllister and coworkers [32] demonstrated that CBD not only
affected breast cancer cell proliferation, but it also interfered with invasion and metastasis, two
other crucial final and fatal steps of breast cancer cell progression. Analysis on three different
groups of cannabinoid compounds (phytocannabinoids with affinity for CB1 and CB2 recep‐
tors; phytocannabinoids with no appreciable affinity for CB1 and CB2 receptors; synthetic
compounds with affinity for CB1 and CB2 receptors) revealed that CBD was shown to be one
of the most effective inhibitors of human breast cancer cell proliferation, being as potent as Δ9-
THC and CP55940 in inhibiting MDA-MB-231 and MDA-MB-436 cell growth respectively, and
resulting as the most potent inhibitor of the MDA-MB-231 cell migration. By the use of Boyden
chamber the authors also investigated the effect of several cannabinoids on the ability of MDA-
MB-231-the most aggressive breast cancer cell line-to migrate and invade a reconstituted
basement membrane: CBD demonstrated once more to be the most potent inhibitor of cell
invasion. Further investigation concerned the identification of the cellular mechanism
underlying CBD effect on cell growth and invasion. CBD was predicted to act through the
regulation of key genes involved in the control of cell proliferation and invasion. In particular,
attention was focused on Id-1 protein, an inhibitor of basic helix-loop helix transcription
factors, which overexpression in breast cancer cells stimulates proliferation, migration and
invasion. In fact, CBD exerted inhibition of Id-1 expression at the same concentrations already
proved to be effective against proliferation and invasion (0.1, 1 and 1.5 μM). It is worth noting
that CBD has no effect on invasiveness in cells that ectopically expressed Id-1. CBD therefore
revealed a non toxic exogenous agent able to significantly decrease Id-1 expression in breast
cancer cells and, at the same time, effective at reducing tumour aggressiveness.
Later work from the same group elucidated the cellular pathways involved in the down-
regulation of Id-1 expression by CBD and leading to inhibition of human breast cancer
proliferation and invasiveness [33]. First of all, they demonstrated that CBD-induced up-
regulation of the extracellular signal-regulated kinase phosphorylation (p-ERK) was respon‐
sible for inhibition of Id-1 expression and subsequent human breast cancer cell proliferation
and invasion. Indeed, the ERK inhibitor, U0126, partially reverted the ability of CBD to inhibit
proliferation and invasion and attenuated its effect on Id-1 expression. Besides ERK up-
regulation, also the production of reactive oxygen species (ROS) seems to play a role in CBD
inhibitory effect on Id-1. In fact, CBD ability to inhibit proliferation, invasion and Id-1 expres‐
sion was reversed by the use of tocopherol, a ROS scavenger. In addition to Id-1, CBD also
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modulates the pro-differentiation factor Id-2, inducing its up-regulation. Consistent with the
work from Ligresti [31], CBD also demonstrated in vivo efficacy: it reduced primary tumour
mass as well as the size and number of metastatic foci in two models of metastasis.
The most recent contribute to the elucidation of the cellular mechanism elicited by CBD to
induce cell death in breast cancer cells comes from an excellent paper of Shrivastava et al. [34].
According to the experiments that they performed on both estrogen receptor positive and
estrogen receptor negative breast cancer cells, CBD (0.1-10 μM for 24 h) induced a concentra‐
tion-dependent cell death. Worth to note, the effective concentrations of CBD in tumour cells
have little effect on MCF-10A cells, a line of non tumourigenic, mammary cells. This effect
resulted to be independent of CB1, CB2 and TRPV1 receptor activation. Cell morphology
assessed through electron microscopy revealed to be consistent with the coexistence of
autophagy and apoptosis. These events were promoted by the induction of endoplasmic
reticulum (ER) stress and the inhibition of Akt/mTOR/4EBP1 signalling. Also ROS production
induced by CBD seems to play a role, since ROS inhibition through tocopherol blocked the
induction of apoptosis and autophagy. Further investigation of the cellular mechanisms
involved in CBD-induced programmed cell death (PCD) demonstrated that this compound
reduced mitochondrial membrane potential, triggered the translocation of the Beclin2
Interacting Protein (Bid) to the mitochondria and the release of cytochrome C to the cytosol
and, ultimately, the activation of the intrinsic apoptotic pathway. The relationship between
CBD-induced apoptosis and autophagic cell death was also explored through blockade of each
form of the PCD with specific caspase and autophagy inhibitors. In the first case, caspase
inhibition reduced CBD pro-apoptotic effect and corresponded to lower levels of protein
markers in breast cancer cells. On the other hand, the inhibition of autophagy enhanced the
level of CBD-induced apoptosis and determined an increase in protein marker expression. As
suggested by these data, blockade of CBD-induced autophagy likely results in a compensatory
increase of apoptosis as an alternative means of PCD. CBD-induced PCD thus depends on a
precise balance between apoptosis and autophagy which could be mediated by Beclin1.
Though its mechanism of action is not clearly elucidated, Beclin1 is considered a key signalling
molecule in the autophagic process. It has been recently suggested that Beclin1 is cleaved by
caspases and that such cleaved form is incapable of inducing autophagy [31,32]. CBD treatment
(5 to 10 μM) resulted in the cleavage of Beclin1. This is consistent with induction of caspases
activity and suggests that Beclin1 may likely have a role in CBD-mediated cell death. The
consequent cleavage product translocates to the mitochondria, where it induces apoptosis by
enhancing the release of cytochrome C [35,36]. The cleavage and consequent translocation of
cleaved Beclin1 to the mitochondria induced by CBD treatment may thus be crucial among
the mechanisms elicited by CBD to modulate the balance between autophagy and apoptosis
in breast cancer cells.
As a whole this work highlights the presence of a complex mutual regulation of autophagy
and mitochondria-mediated apoptosis in CBD-induced breast cancer cell death. The very
promising data here reported support the idea that this non toxic compound could likely
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represent either a new therapeutic opportunity for breast cancer treatment or the starting point
for a second generation compound to be tested in clinic.
In Figure 3 it is depicted a schematic representation of the signalling pathways associated with
CBD effect in breast cancer cell proliferation and invasion.
Figure 3. Schematic representation of the signalling pathways associated with CBD effects on breast cancer (with the
permission of the authors [30])
5. CBD and glioma
Moreover, CBD also exhibited anti-tumoural properties in gliomas, a class of brain tumours
of glial origin characterized by a high morphological and genetic heterogeneity accounting for
over 30% of all primary brain tumours. Gliomas are characterized by a high proliferative rate,
aggressive invasiveness and insensitivity to radio-and chemotherapy, and are considered
among the most rapidly growing and devastating solid tumours.
In a seminal paper Jacobsson et al. [37] first demonstrated that CBD displayed a serum-
dependent effect on C6 murine glioma cell proliferation. Massi et al. [38] afterwards reported
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in 2004 an effective inhibition of U87-MG and U373 human glioma cell proliferation in vitro
following CBD treatment, associated with the induction of apoptosis. Exposure of both cell
lines to CBD for 24 h induced a concentration-and time-dependent inhibition of the mitochon‐
drial oxidative metabolism, with an IC50 value of 25 μM. The authors then evaluated the effect
of intratumoural in vivo treatment with CBD, in tumour xenografts generated by subcutaneous
injection of glioma cells in the flank region of immune-deficient mice. The treatment caused a
significant reduction (60% mean) of the tumour growth over a 23-day period of observation
[38]. Data from flow-cytometric analysis and ssDNA detection assay indicated that this
reduction was correlated to CBD ability to induce a PCD. Of note, subsequent investigation
demonstrated that CBD as no effect on the viability of non transformed primary glial cells [39].
Analysis of the cellular mechanisms responsible for CBD anti-proliferative effect demonstrated
the lack of significant stimulation of cannabinoid and vanilloid receptors [38]. The sole CB2
receptor antagonist SR144528 only weakly and transiently reverted CBD effect, a partial
antagonism being present only over a 24 h-period and restricted to just one glioma cell lineage.
Further data from the same work demonstrated for the first time that CBD anti-tumour effect
depend on its ability to induce an oxidative stress state in the tumour cells: indeed this molecule
induced an elevated and early production of ROS, a corresponding depletion of intracellular
glutathione and an increase of activity of the GSH-associated enzymes. Consistent with these
evidences, the anti-proliferative effect of the drug was reversed by the anti-oxidant, tocopherol.
It is worth noting that CBD did not affect ROS production in non transformed primary glial
cells [39]. Subsequent investigation of the cellular events implicated in glioma cell death
demonstrated that CBD induces a time-dependent release of cytochrome C and activation of
caspase-8, caspase-9 and caspase-3: both the intrinsic and the extrinsic pathways of apoptosis
result therefore involved in CBD effect [39].
Further support to the efficacy of CBD in inhibiting the growth of different glioblastoma cell
lines (SF126, U251 and U87-MG) comes from a work from Marcu et al. [40]. In their paper the
authors demonstrated not only that CBD appears more potent that Δ9-THC, but also that
combination treatment of Δ9-THC with CBD determined an enhancement of Δ9-THC inhibitory
effect on glioblastoma cell growth, but not on invasiveness [40]. Accordingly, Torres et al. [41]
recently confirmed that association of CBD with Δ9-THC treatment greatly reduced the
viability of several human glioma cells and determined an enhancement of both autophagy
and apoptosis, with corresponding triggering of caspase-3 activation. Exposure of xenografts
generated from U87-MG cells in nude mice to submaximal concentrations of CBD in combi‐
nation with Δ9-THC inhibited tumour growth at a higher extent than the treatment with the
individual compounds: these data suggest a potential use of the combinatory therapy as a
strategy to allow reduction of the amount of the psychoactive Δ9-THC in potential cancer
treatment.
The cellular mechanism involved in the synergistic action of the combined therapy were
investigated by Marcu et al. [40]: double treatment with CBD and Δ9-THC in vitro induced cell
cycle arrest, stimulation of ROS production and sustained activation of caspases-3,-7 and-9,
with consequent induction of apoptosis, together with specific modulation of the extracellular
signal-regulated kinase, ERK. Exposure to each individual compound was unable to induce
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these specific effects, suggesting that the signal transduction pathways affected by the
combination treatment were unique. Recent results form Parolaro’s group [42] apparently
disagree with Marcu’s data, as in their hands CBD per se strongly down-regulates ERK, as well
as another signalling molecule playing a crucial role in tumour cell proliferation, such as PI3K/
Akt, both in U87-MG cells and in cannabinoid-resistant T98G human glioma cell lines.
Moreover, CBD also profoundly down-regulated the hypoxia-inducible transcription factor
HIF-1α, one of the most critical stimuli for cell survival, motility and tumour angiogenesis.
These evidences suggest that HIF-1α, together with ERK and Akt, represent three of the
multiple molecular targets through which the CBD exerts its anti-neoplastic activity [42].
Talking about the mechanisms elicited by CBD to prevent glioma growth, further ex vivo
investigations, performed on glioma tumour tissues excised from nude mice treated in vivo
with CBD, showed its ability to modulate the lipoxygenases (LOX) pathway and the endo‐
cannabinoid system [43]. Biochemical analysis indicated a significant decrease of 5-LOX
activity and content and of its end-product leukotriene B4, as well as a marked stimulation of
the fatty acid amide hydrolase (FAAH), and a decrease of AEA content. In contrast, cycloox‐
ygenase (COX)-2 activity and content were not affected by CBD.
CBD ability to reduce tumour growth is not only restricted to cell proliferation, but several
data also support its effects on glioma cell migration and invasiveness. As a matter of fact, CBD
inhibited U87-MG glioma cells migration in a concentration-dependent way, at concentrations
lower than those required to inhibit cell proliferation [44]. Treatment with the selective
cannabinoid receptor antagonists SR141716 (CB1), SR144528 (CB2) or by pretreatment with
pertussis toxin were not able to antagonize CBD anti-migratory effect, thus indicating no
involvement of classical cannabinoid receptors and/or Gi/o protein coupled receptors. Cell
invasiveness, evaluated through a reconstituted basement membrane in a Boyden chamber
test, was reduced after CBD treatment in U251 glioma lineage [40].
Worth to note, an activation of TRPV2 receptor by CBD have recently [45] demonstrated to
inhibit human glioma cell proliferation and overcome carmustine resistance of glioma cells.
This mechanisms seems to involve increase in Ca2+influx and consequent drug uptake,
synergizing with cytotoxic agents to induce apoptosis of glioma cells. Interestingly this effect
was limited to tumour cells, whereas it is absent in normal human astrocytes.
At last, Soroceanu and coworkers [46] recently investigated the role of the transcriptional
regulator Id-1 in modulating the invasiveness of glioma cells. As previously reported for breast
cancer, Id-1 expression levels positively correlate with glioma cell invasiveness in culture and
with histopathological grades in patient biopsies. The authors showed that CBD significantly
down-regulates Id-1 gene expression and associated glioma cell invasiveness and self-renewal,
and glioma progression in vivo, thus suggesting that Id-1 may be an additional target for CBD.
As a whole, CBD seems to counteract glioma cell proliferation and invasion through multiple
mechanisms. Most of them are summarized in Figure 4.
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Figure 4. Schematic representation of the signalling pathways associated with CBD effects on glioma
6. CBD and leukaemia/lymphoma
Gallily et al. [47] first evidenced the possible role of CBD in the treatment of lymphoblastic
diseases. They demonstrated that 24 h-treatment with CBD induced apoptosis in human acute
myeloid leukaemia HL-60 cell line: the effect was dose-dependent and involved caspase-3
activation. On the contrary, CBD treatment had no effect on human monocytes from normal
individuals.
By far the most important work in this field was from McKallip et al. [48]. They exposed the
murine EL-4 lymphoma cell line and the human Jurkat and Molt-4 leukaemia cell lines to CBD
(1-10 μM) and demonstrated that this compound is able to reduce the number of viable cells
and to induce apoptosis, both in vitro and in vivo, in a CB2 receptor dependent way. In
particular, treatment with CBD in vivo led to a significant reduction in tumour burden and
determined a higher level of apoptotic tumours in EL-4-bearing mice [48].
As far as the cellular mechanisms are concerned, CBD effect on Jurkat cells in vitro involved
the activation of caspase-8, caspase-9, and caspase-3, caused the cleavage of poly(ADPribose)
polymerase, and corresponded to a decrease in full-length Bid: these concerted events support
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a possible cross-talk between the intrinsic and extrinsic apoptotic pathways. CBD exposure
caused a loss of mitochondrial membrane potential and the subsequent release of cytochrome
C, thus further confirming the crucial role of mitochondria in PCD regulation by CBD.
Moreover, as previously observed in other tumour cells, CBD treatment corresponded to an
increase of ROS production as well as in the expression of the NAD(P)H oxidases Nox4 and
p22phox. Treatment with the ROS scavengers or the NAD(P)H oxidase inhibitors prevented both
CBD-mediated induction of apoptosis and ROS increase. Finally, CBD down-regulated
phosphorylation and consequent activation of p38 mitogen-activated protein kinase, but did
not affect p-ERK and p-JNK levels. Exposure to a CB2-selective antagonist or to a ROS
scavenger reverted this effect, thus suggesting that CBD may involve CB2 receptors and
regulation of Nox4 and p22phox expression in its action [48].
As a whole, CBD may represent a novel and highly selective candidate for leukaemia treat‐
ment. It is worth noting that previous evidences indicated that human leukaemias and
lymphomas expressed significantly higher levels of CB2 receptors compared to other tumour
cell lines. For this reason the observation that CBD mediates apoptosis through CB2 receptors
is particularly relevant, suggesting the possibility that tumours of immune origin may be
highly sensitive to the CB2-mediated effects of CBD [49].
7. CBD and lung cancer
Lung cancer is characterized by a particularly aggressive biological nature and is, at present,
poorly responsive to available therapy. For this reason, a series of targets and therapeutic
strategies for its treatment are currently being investigated [50-53].
Ramer’s research group is one of the most active interested in preclinical lung cancer research.
They recently [54-56] evaluated CBD effects on A549 cells, a line of human lung carcinoma
cells expressing both CB1 and CB2, as well as TRPV1 receptors, with particular focus on
invasiveness. By the use of Matrigel invasion assay, they demonstrated that CBD induces an
impaired invasion of A549 cells; this impairment was reversed by antagonists to both CB1 and
CB2 receptors as well as to TRPV1. Moreover, they observed that invasion decrease determined
by CBD treatment corresponded to an upregulation of tissue inhibitor of matrix metallopro‐
teinases-1 (TIMP-1); on the other hand, knocking down of TIMP-1 expression through a siRNA
approach was able to reverse the CBD-elicited decrease in tumour cell invasiveness. These
evidences suggest that there may be a causal link between the TIMP-1 up-regulation and CBD
anti-invasive action. CBD was also shown to induce phosphorylation of two mitogen-activated
protein kinases, p38 and p42/44: these have been identified as upstream mechanisms leading
to TIMP-1 induction and subsequent decrease of invasiveness. Interestingly, these events are
all prevented by exposure to cannabinoids or TRPV1 receptor antagonists.
The authors also performed in vivo studies in thymic aplastic nude mice [54]: in such model,
intravenous injection of CBD at a dose of 5 mg/kg in animals caused a significant inhibition of
A549 lung metastasis, further supporting the possible therapeutic benefit of CBD adoption.
Together with the strong inhibition of A549 cell invasion, CBD treatment induced a corre‐
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sponding down-regulation of the plasminogen activator inhibitor PAI-1 expression and
secretion, another factor playing an important role in the regulation of cell spreading [55].
CBD-driven decrease in PAI-1 secretion and cell invasion were suppressed by exposure to
CB1 and CB2 receptors as well as to TRPV1 receptor antagonists. Recombinant human PAI-1
led to a concentration-dependent up-regulation of invasiveness, while PAI-1 siRNA caused
down-regulation, suggesting a crucial role of PAI-1 in A549 invasiveness. The same experi‐
ments were also performed in two other human lung cancer cell lines, H460 and H358, and
key data were confirmed.
PAI-1 also revealed crucial in vivo: CBD treatment (5 mg/kg) of A549 xenografts of rats
determined its significant down-regulation [55].
One of the most important aspects in these works resides in the dose-range at which CBD
effectively inhibits invasion. In fact, treating human lung cancer cells for 72 h with CBD the
authors observed a significant effect at a concentration as low as 0.01 μM, corresponding to a
33% inhibition when compared to control vehicle. At the same conditions [56] an equimolar
concentration of Δ9-THC caused a 68% inhibition of cell invasion. Nonetheless, it is worth
noting that CBD anti-invasive effect occurred in a range of therapeutically relevant concen‐
trations: as a matter of fact, as reported from a clinical study on healthy volunteers, CBD
reached peak plasma concentrations between 0.01 μM and 0.05 μM following administration
of SativexTM (1:1 ratio of Δ9-THC and CBD) at the buccal dose of 10 mg or at the self-titrated
doses during chronic therapy [57].
In their most recent work, Ramer et al. [58] demonstrated that CBD reduces cell viability in
lung cancer cell lines (A549, H460) and primary cells from a patient with lung cancer, this effect
being associated with apoptosis. The cellular mechanisms induced by CBD involve an initial
up-regulation of COX-2 and PPAR-γ, both in vitro, in A549 and H460 cell lines, and in vivo, in
A549-xenografted nude mice, and a subsequent nuclear translocation of PPAR- by COX-2-
dependent prostaglandins.
As a whole, these evidences contribute to elucidate the mechanisms underlying CBD anti-
invasive action on human lung cancer cells and strongly support its possible use as a thera‐
peutic option for the treatment of highly invasive types of cancers.
8. CBD and endocrine tumours
Among the endocrine malignancies, the most common one is thyroid cancer. This kind of
tumour is characterized by overactivation of Ras, that may depend on activating mutations in
the ras gene or on overactivation of receptor tyrosine kinase receptors. According to these
observations, new strategies for the treatment of thyroid cancer should reasonably point at Ras
as crucial molecular target.
Ligresti et al. [31] first exposed KiMol cells – rat thyroid cells transformed with the v-K-ras
oncogene – to CBD treatment: this phytocannabinoid caused anti-proliferative effects in
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association with a cell cycle block at the G1/S phase transition, which was accompanied by a
pro-apoptotic action.
Further studies from Lee et al. [59] demonstrated a marked CBD pro-apoptotic effect in both
murine thymocytes and EL-4 thymoma cells: this effect was time-and concentration-related.
In particular, according to time-course analyses, CBD-mediated apoptosis occurred earlier in
EL-4 cells than in thymocytes. The cellular events triggered by CBD were similar in both T
cells: ROS generation played a pivotal role, although the basal level of ROS in thymocytes was
lower than that in EL-4 cells. Exposure to the glutathione precursor N-acetyl-L-cysteine (NAC)
markedly attenuated CBD-driven induction of apoptosis, and reverted the decrease of cellular
thiols levels.
In conclusion, unlike monocytes, T cells, both primary and immortalized, are all sensitive and
similarly responding to CBD, as demonstrated by the fact that CBD induced oxidative stress
in thymocytes, EL-4 cells and splenocytes [60]. ROS generation proved to play a central role
in this response.
9. CBD and colon cancer
Colon cancer is one of the principal causes of morbidity and mortality in Western countries.
Its aetiology seems to reside in a series of histopathological and molecular changes that
transform normal colonic epithelial cells, give rise to Aberrant Crypt Foci (ACF) and polyps
as intermediate steps, and at last develops a colorectal carcinoma.
First investigation about CBD effect on SW480 colon and LNCaP prostate carcinoma cells
comes from Sreevalsan et al. [61]. They demonstrated that CBD inhibits cell growth in both
cell lines. This anti-proliferative effect corresponds to an induction of apoptosis. Moreover,
CBD induced mRNA expression of several dual specificity phosphatases and protein tyrosine
phosphatases. This is particularly relevant given that the anti-tumoural effects of many
cannabinoids include modulation of intracellular kinase. The pro-apoptotic activity of CBD
was phosphatase-dependent in both cell lines, on the other hand, cannabinoid receptors
mediated its effects only in prostate cancer cells, whereas their role in colon carcinoma is
controversial.
Izzo and coworkers recently [62] investigated the effect of CBD in a preclinical animal model
of colon cancer based on azoxymethane (AOM) administration in mice. AOM causes in
exposed cells occurrence of ACF (preneoplastic lesions), polyps, and tumour formation, as well
as up-regulation of p-Akt, iNOS and COX-2 and the down-regulation of caspase-3. The authors
demonstrated that CBD possesses effective chemopreventive properties: it reduced ACF,
polyps and tumours and counteracted AOM-induced p-Akt and caspase-3 changes. Moreover,
in vitro studies performed in colorectal carcinoma cell lines evidenced that CBD protected DNA
from oxidative damage, increased endocannabinoid levels and reduced cell proliferation in a
CB1-, TRPV1-and PPAR-γ-antagonists sensitive manner.
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Based on these promising data and on its safety records, it is likely to consider CBD a worthy
candidate for clinical consideration in colon cancer prevention.
10. CBD and angiogenesis
More and more evidences indicate that a new promising therapeutic target for cancer therapy
is represented by angiogenesis, the formation of new blood vessels from the pre-existing ones.
Moreover, tumour angiogenesis is target of several cannabinoids, which not only down-
regulate the production of pro-angiogenic factors in cancer cells, but also directly modulate
endothelial cell growth [27]. It is hence surprising the lack of any data on CBD ability to
influence angiogenesis.
As Solinas et al. recently demonstrated [63], CBD is a potent inhibitor of HUVE cell prolifer‐
ation, migration and invasion, acting through the induction of endothelial cell cytostasis, but
without triggering apoptosis. Interestingly, CBD affected endothelial cell differentiation into
tubular capillaries and blocked the outgrowth of capillary-like structures from HUVEC
spheroids in vitro. Moreover, CBD anti-angiogenic effect was also evident in vivo in a matrigel
sponge model. The cellular mechanisms elicited seem to involve down-modulation of several
molecules associated with angiogenesis, including MMP2 and MMP9, uPA, Endothelin-1,
PDGF-AA and CXCL16.
These preliminary data are very promising and demonstrate for the first time that, besides its
well known pro-apoptotic anti-proliferative and anti-invasive actions, CBD may also exert
anti-angiogenic effects, thus further strengthening its potential application in cancer therapy.
11. Conclusion
Much interest has been addressed to CBD since it is a plant-derived cannabinoid devoid of
psychoactive properties. Many evidences support its pro-apoptotic and anti-proliferative
actions in different types of tumours, as well as its anti-migrative, anti-invasive, anti-metastatic
and perhaps anti-angiogenic properties. This wide range of anti-tumour effects indicate that
CBD may likely be a potent inhibitor of both cancer growth and spreading.
In this regard, it is worth noting that, at least in vitro, this compound seems to exert its anti-
cancer effect selectively on cancer cells, without affecting normal cell viability. Moreover, CBD
revealed extremely efficient in inhibiting tumour growth: its versatility can be ascribed to the
modulation of multiple cellular pathways that control tumourigenesis and consequent altering
of different intracellular signalling, depending on the cancer type considered.
In particular, among all, increase in ROS production appears to be one of the most common
and crucial mechanisms induced by CBD to exert its effects in all of the considered cancer cell
lines. Less obvious is the role of cannabinoid and vanilloid receptors in mediating CBD action.
In some cases (lung, leukaemia, colon) exposure of the cells to specific antagonists clearly
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demonstrated the essential contribution of these receptors. In other kinds of cancer (breast and
glioma) their relevance appears only marginal or absent.
Of note, CBD demonstrated to efficiently inhibit cancer development not only in vitro, but also
in several in vivo tests, determining reduction of tumour growth and, in some cases, of
metastatization.
Nonetheless, the opportunity to introduce CBD in clinical practice for cancer treatment needs
some consideration. A good starting point comes from high tolerability and from the lack of
toxic effects. Indeed oral administration of CBD 700 mg/day for 6 weeks did not show any
overt toxicity in humans [64] suggesting its possible exploitation for prolonged treatment. On
the other hand, CBD oral absorption is slow and unpredictable, making it difficult to realize
the optimal route of administration. Previous trials indicated that 6 weeks of oral CBD
treatment 10 mg/kg/day induced a mean plasma level of CBD between 6 and 11 ng/ml (about
0.0036 μM) [65] and that this value did not differ significantly over the 6 weeks of adminis‐
tration. Of note, this same range of concentration was effective in inhibiting lung cancer cell
invasion [55,56]: for instance in this case, the oral route could be the appropriate choice.
Moreover, according to experimental data showing that combined treatment with CBD and
Δ9-THC could be more effective in reducing cancer cell proliferation, the co-administration
may represent a better choice for cancer therapy. In line with this, oromucosal treatment with
SativexTM 10 mg (a formulation consisting of 1:1 ratio of Δ9-THC and CBD and recently
approved for multiple sclerosis) provoked CBD plasma level of approximately 0.01 μM and
up to 0.05 μM in humans, a concentration range effective in reducing lung cell invasion in
vitro. As reported, the use of different associations of phytocannabinoids in a variable propor‐
tion might lead to a better outcome without pharmacokinetic interaction [66]. Another
favourable aspect of oromucosal administration is its possible application in presence of
nausea and vomiting. In view to overcome the several limitations to the systemic administra‐
tion of cannabinoids in part derived from their high lipophilicity, a recent work from Hernán
Pérez de la Ossa et al. [67] investigated the effects of CBD-and ∆9THC-loaded poly-ε-capro‐
lactone microparticles as an alternative delivery system for long-term cannabinoid adminis‐
tration in a murine xenograft model of glioma. Local administration of ∆9-THC-, CBD-or a
mixture (1:1 w:w) of ∆9THC- and CBD-loaded microparticles every 5 days to mice bearing
glioma xenografts reduced tumour growth with the same efficacy than a daily local adminis‐
tration of the equivalent amount of those cannabinoids in solution. Moreover, treatment with
cannabinoid-loaded microparticles enhanced apoptosis and decreased cell proliferation and
angiogenesis in these tumours.
Moreover, it would be worth evaluating the possibility to use CBD (or Sativex) in combination
with classical chemotherapeutic agents: this would enable to check for the presence of a
synergistic effect that might potentially allow clinical chemotherapeutic dose reduction, and
consequently reduce toxicity while maintaining efficacy.
Bearing in mind that CBD is already currently used in patients with multiple sclerosis, and in
light of the findings here summarized, it can be concluded that CBD might be a good candidate
for a future clinical approach and/or for the synthesis of a second generation compound, as
suggested by McAllister’s group. In view of these opportunities and based on the data here
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presented, further research should be addressed to continue exploration of CBD and/or of CBD
analogues as alternative agents for cancer therapy.
Nomenclature
The drug/molecular target nomenclature conforms to the BJP’s Guide to Receptors and
Channels [68].
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